Amphastar Pharmaceuticals... (AMPH)
Amphastar Pharmaceuticals Statistics
Share Statistics
Amphastar Pharmaceuticals has 47.65M shares outstanding. The number of shares has increased by -0.03% in one year.
| Shares Outstanding | 47.65M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -1.22% |
| Owned by Institutions (%) | 72.85% |
| Shares Floating | 35.19M |
| Failed to Deliver (FTD) Shares | 503 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 4.6M, so 9.57% of the outstanding shares have been sold short.
| Short Interest | 4.6M |
| Short % of Shares Out | 9.57% |
| Short % of Float | 12.85% |
| Short Ratio (days to cover) | 6.58 |
Valuation Ratios
The PE ratio is 11.27 and the forward PE ratio is 9.06. Amphastar Pharmaceuticals's PEG ratio is 0.73.
| PE Ratio | 11.27 |
| Forward PE | 9.06 |
| PS Ratio | 2.52 |
| Forward PS | 1.6 |
| PB Ratio | 2.46 |
| P/FCF Ratio | 10.43 |
| PEG Ratio | 0.73 |
Enterprise Valuation
Amphastar Pharmaceuticals Inc. has an Enterprise Value (EV) of 3.46B.
| EV / Earnings | 21.72 |
| EV / Sales | 4.86 |
| EV / EBITDA | 12.49 |
| EV / EBIT | 16.86 |
| EV / FCF | 20.1 |
Financial Position
The company has a current ratio of 3.07, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.07 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.26 |
| Cash Flow / Debt | 4.36 |
| Interest Coverage | 6.77 |
Financial Efficiency
Return on equity (ROE) is 0.22% and return on capital (ROIC) is 22.18%.
| Return on Equity (ROE) | 0.22% |
| Return on Assets (ROA) | 0.1% |
| Return on Capital (ROIC) | 22.18% |
| Revenue Per Employee | $351,486.19 |
| Profits Per Employee | $78,658.28 |
| Employee Count | 2,028 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.2 |
Taxes
| Income Tax | 29.67M |
| Effective Tax Rate | 0.16 |
Stock Price Statistics
The stock price has increased by -35.14% in the last 52 weeks. The beta is 0.77, so Amphastar Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | -35.14% |
| 50-Day Moving Average | 31.32 |
| 200-Day Moving Average | 40.8 |
| Relative Strength Index (RSI) | 44.29 |
| Average Volume (20 Days) | 593.11K |
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 712.81M and earned 159.52M in profits. Earnings per share was 3.29.
| Revenue | 712.81M |
| Gross Profit | 373.86M |
| Operating Income | 205.42M |
| Net Income | 159.52M |
| EBITDA | 277.31M |
| EBIT | 205.42M |
| Earnings Per Share (EPS) | 3.29 |
Balance Sheet
The company has 151.61M in cash and 48.92M in debt, giving a net cash position of 102.69M.
| Cash & Cash Equivalents | 151.61M |
| Total Debt | 48.92M |
| Net Cash | 102.69M |
| Retained Earnings | 568.79M |
| Total Assets | 1.58B |
| Working Capital | 360.31M |
Cash Flow
In the last 12 months, operating cash flow was 213.39M and capital expenditures -41.04M, giving a free cash flow of 172.34M.
| Operating Cash Flow | 213.39M |
| Capital Expenditures | -41.04M |
| Free Cash Flow | 172.34M |
| FCF Per Share | 3.56 |
Margins
Gross margin is 52.45%, with operating and profit margins of 28.82% and 22.38%.
| Gross Margin | 52.45% |
| Operating Margin | 28.82% |
| Pretax Margin | 26.62% |
| Profit Margin | 22.38% |
| EBITDA Margin | 38.9% |
| EBIT Margin | 28.82% |
| FCF Margin | 24.18% |
Dividends & Yields
AMPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 11.55% |
| FCF Yield | 12.7% |
Analyst Forecast
The average price target for AMPH is $43.5, which is 52.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $43.5 |
| Price Target Difference | 52.7% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 2.64 |
| Piotroski F-Score | 5 |